Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis

Author(s): Rashi Chauhan, Gulshan Wadhwa, Sanjeev K. Sharma, Chakresh K. Jain.

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 9 , Issue 2 , 2014

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Coxiella burnetii is an infectious and etiological agent responsible for causing Q fever. There are mainly two forms of the Q fever that are chronic and acute. Though the acute type is usually linked with symptoms like pneumonia and hepatitis, the chronic form is shown to have mortality rate of 5%. Percentage of mortality rate might increases from 5% to 25% if left untreated. The present treatments of disease include the recommended dose of drugs and vaccine. Presently, extensive attempt is in progress to find novel therapies to combat the disease. This review is projected to provide a brief introduction of C. burnetii and Q fever while emphasizing therapeutics, prophylactic measures and diagnostic applications based on recent patents prospects.

Keywords: Antibodies, Coxiella burnetii, doxycycline, fluoroquinolone, therapeutics, vaccines.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 2
Year: 2014
Page: [104 - 111]
Pages: 8
DOI: 10.2174/1574891X09666141114222644
Price: $58

Article Metrics

PDF: 23